ACCELERATE

• Research type

  Research Study

• Full title

  Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study

• IRAS ID

  111935

• Contact name

  John Betteridge

• Sponsor organisation

  Eli Lilly and Company

• Eudract number

  2012-000061-21

• Research summary

  The purpose of the study is to determine if the study drug (Evacetrapib) is effective in people with high risk vascular disease. This study will enrol 11000 patients worldwide. The anticipated median duration of treatment is approximately 3 years with more than 80% of patients expected to complete at least 2.5 years of follow-up. The maximum duration of treatment is expected to be up to 4 years. Participation will include 19 visits and an unscheduled visit. During these visits patients will undergo a number of procedures to confirm the safety and the effectiveness of the study drug (including vital signs, physical examination, ECG, and blood collection for laboratory tests). The study will be conducted at 8 sites in the UK, including GP surgeries, and hospitals.

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  12/YH/0398

• Date of REC Opinion

  25 Oct 2012

• REC opinion

  Further Information Favourable Opinion